论文部分内容阅读
日本27个临床单位对Tosufloxacin(T-3262)和巴卡西林(BAPC)治疗妇产科感染的有效性、安全性和有用性进行了双盲比较研究。研究对象为子宫内感染、子宫附件炎 (A组),和前庭大腺炎、脓肿(B组)。每天给药量,T-3262为450mg(分3次),BAPC为1000mg(分3次)。疗程原则上均为7天。进行有效性评价的病例共168例(T-3262组80例,BAPC组88例)。经委员会判定,T-3262组有效率为90.0%,BAPC组为68.2%,T-3262组明显优于后者。 A组中经T-3262治疗的52例有效率为90.4%,经BAPC治疗的59例为71.2%;B组
A double-blind comparative study of the efficacy, safety and usefulness of Tosufloxacin (T-3262) and bacalicillin (BAPC) in the treatment of gynecological and obstetric infections in 27 Japanese clinical units was conducted. The subjects were intrauterine infection, uterine attachment inflammation (group A), and bartholinitis, abscess (group B). The daily dose, T-3262 is 450mg (divided three times), BAPC is 1000mg (divided three times). The course of treatment is 7 days in principle. A total of 168 cases were evaluated for effectiveness (80 in the T-3262 group and 88 in the BAPC group). The committee determined that T-3262 group was 90.0%, BAPC group was 68.2%, T-3262 group was significantly better than the latter. In group A, the effective rate of T-3262 in 52 cases was 90.4%, in BAPC-treated group, 59 cases were 71.2%; in group B